FDA advisers are reviewing a multicancer-detection test. Medicare coverage could follow.
MarketWatchPaywall
Read Full Article at MarketWatch →Ad Slot — In-Article (728x90)
Grail’s Galleri test looks for 50 cancers from a blood draw, but a major study failed to prove it could detect later-stage cancers.
This is a summary. For the full story, read the original article at MarketWatch.
Original source: MarketWatch